Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244161 | 1.00 | NPY4R (0.45) | NPY4RNPY1RANPEPRNPEPDNPEP | |
| SCHEMBL28712062 | 0.89 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL288133 | 0.89 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL9237239 | 0.89 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL1821005 | 0.88 | NPY4R (0.40) | NPY4RNPY1RANPEPRNPEPDNPEP | |
| SCHEMBL2125107 | 0.88 | NPY4R (0.39) | NPY4RNPY1RANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL8039440 | 0.88 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| Hydrochloric Acid SCHEMBL8040222 | 0.88 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL15653883 | 0.87 | NPY4R (0.41) | NPY4RNPY1RANPEPRNPEPDNPEP | |
| SCHEMBL30531669 | 0.87 | NPY4R (0.41) | NPY4RNPY1RANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-102516382-B | Antimicrobial peptide Hainanenin-5 of Amolops hainanensis, gene of antimicrobial peptide Hainanenin-5 of Amolops hainanensis, and application of gene of antimicrobial peptide Hainanenin-5 of Amolops hainanensis | UNIV DALIAN TECH | 2014-04-16 | — | — | CN | claimed |
| WO-2008058016-A2 | ETHOID-CONTAINING COMPOUNDS, METHODS FOR PREPARING ETHOID-CONTAINING COMPOUNDS, AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-15 | — | — | WO | claimed |
| EP-0388226-B1 | Means for the treatment of senile dementia, memory disorders and related conditions | AJINOMOTO KK (JP) | 1995-08-09 | — | — | EP | claimed |
| CN-113167803-B | In-vitro detection method for intestinal dysbiosis of poultry | 赢创运营有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117582457-A | Application of bacillus coagulans BC168 in preparation of clostridium perfringens inhibiting preparation and application of bacillus coagulans BC168 in production of chicken intestinal tracts and broiler chickens | 广东容大生物股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022213201-A1 | APPARATUS AND METHODOLOGIES FOR DETECTION, DIAGNOSIS, AND PROGNOSIS OF BRAIN INJURY | UTI LIMITED PARTNERSHIP (CA) | 2022-10-13 | — | — | WO | disclosed |
| CN-114630818-A | Protein-macromolecule conjugates and methods of use thereof | 北京轩义医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| EP-0979310-B1 | MUTATIONS IN THE katG GENE USEFUL FOR DETECTION OF M. TUBERCULOSIS | MAYO FOUNDATION (US) | 2002-03-13 | — | — | EP | disclosed |
| US-5658733-A | Detection of isoniazid resistant strains of M. tuberculosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0021766-B1 | INHIBITORS OF MAMMALIAN COLLAGENASE | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4297275-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1981-10-27 | — | — | US | disclosed |
| US-4235885-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4086136-A | Process for producing a peptide using a serine or thiol proteinase | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | NPY4R 4239/4885NPY1R 4034/4885ANPEP 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.